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Introduction 
Breast cancer is a common condition; the incidence of which increases with 
age.  In the United Kingdom over 40,000 women are diagnosed with breast 
cancer annually and 30% of these are aged 70 or older.  A number of studies 
have clearly demonstrated that older patients do not receive standard 
approaches to either local or adjuvant treatment 1-6.  More recent studies 
demonstrate that it is the group of women over the age of 75 or 80 at 
diagnosis who are failing to receive standard therapy.7 There are very few 
research trials to inform the surgical management of such patients.  There is 
evidence that this under treatment results in a significantly worse prognosis 
(Fig 1).8 There is an emerging consensus that older women should be 
managed in a similar fashion to younger patients with regards to surgical 
treatment, 9 but special consideration should be given to those patients who, 
(through reasons of co-morbidity or extreme age), have a very limited life 
expectancy.  In such cases consideration may be given, after appropriate 
multi-disciplinary assessment, to alternative approaches.  The factors 
influencing these decisions are reviewed herein. 
 
Tumour biology and stage at presentation. 
As reviewed elsewhere in this special edition of Clinical Oncology there is 
evidence that the biological behaviour of breast cancer may be more 
favourable in older patients with an increased proportion of tumours 
demonstrating oestrogen receptor positivity and a reduction in the incidence 
of HER2 expression.10 However, these favourable characteristics may be 
offset by a later stage at presentation: Older patients present with larger 
   
primary tumours and an increased incidence of locally advanced and 
metastatic disease.   Some studies demonstrate an increased incidence of 
axillary node positivity whilst others report a reduced incidence of axillary 
node involvement.11,12 The reasons for later stage at presentation may relate 
to reduced screening  uptake, 13,14 and patient  related delays in diagnosis,  
possibly partly due to reduced breast awareness.15 
 
Impact of breast cancer on survival in older women 
Until the late 70’s standard management of elderly breast cancer patients 
relied on surgical excision of the primary16 until a publication by a Scottish 
research group proved the efficacy of Tamoxifen in  this age group.  This 
approach rapidly gained acceptance and in
17
 the 1980’s the prevailing view in 
the United Kingdom and some other countries was that a diagnosis of breast 
cancer in patients over the age of 70 had little or no impact on survival.  This 
view, combined with the concept that breast cancer was a systemic disease at 
diagnosis, resulted in a significant reduction in the rates of surgical treatment 
of primary breast cancer in women over the age of 70.  
 
There is evidence that survival in older women with breast cancer is 
substantially worse than in younger women.5 Whilst a significant proportion of 
this mortality may be due to deaths from competing causes breast cancer will 
be the most likely cause of death in the majority of patients with this 
diagnosis.  The exceptions are women with significant co-morbidity or at the 
extremes of older age who have a reduced life expectancy of less than 5 
years.6,18 
   
There is little known about survival outcomes in older breast cancer patients, 
other than that overall survival is substantially worse due to the increased 
incidence of non-breast cancer deaths.  Breast cancer specific mortality in this 
age group is much more difficult to determine from the literature.  This is due 
to the fact that outcomes are rarely adjusted to reflect patient co-morbidity, 
there is widespread disease under-staging in older women as many either 
have no surgery or limited surgery, (often excluding axillary staging) and 
lastly, treatment is often non-standard compared with younger patients.  All of 
these factors result in inaccurate or misleading comparisons with younger 
women's’ outcomes.  Further research is therefore required to define the 
precise relationship between age of diagnosis and survival in breast cancer. 
 
Impact of age on suitability for surgical treatment 
Ageing has significant effects on normal physiological processes independent 
of any associated disease processes, (senescence).  These include 
reductions in cardiac, respiratory and renal reserve in addition to an increased 
incidence of cognitive impairment.  These factors alone may serve to limit 
quality of life and suitability for certain adjuvant treatments such as cytotoxic 
chemotherapy.  However, the morbidity associated with surgery for breast 
cancer is minimal and these physiological considerations are rarely a 
significant factor in determining whether a patient should be considered 
eligible for surgical treatment.19 
 
In addition to the above mentioned senescent organ impairment, co morbid 
diseases are increasingly common with age and may significantly impact on 
   
life expectancy and treatment tolerance.6,18 A number of scoring systems 
have been developed  to predict life expectancy and guide treatment decision-
making in the elderly. These include the Charlson Index which combines the 
number and severity of a defined selection of co-morbid diseases and can 
predict mortality with modest accuracy.20. More recently tools such as the 
Comprehensive Geriatric Assessment and the Multidimensional Assessment 
for Cancer in the Elderly (MACE) have been developed.  These include a 
detailed assessment of co-morbidity, functional status, cognitive function and 
depression scores.21,22 Measures of global functional ability have also been 
shown to be independently useful in predicting life expectancy.  For example, 
the Activities of Daily Living (ADL),  the Instrumental Activities of Daily Living 
(IADL) and the Mini Mental State Examination (MMSE) scores  have all been 
shown to have prognostic value.23-25 These tools are relatively time 
consuming to administer and require specialist interpretation and may be 
outside the experience of most surgeons treating breast cancer.  They are 
best utilised in the assessment of frail elderly patients where initial screening 
in a standard breast clinic indicates that life expectancy may be limited raising 
questions about the choices and efficacy of treatment. 
 
Does surgical treatment improve survival and local control in older 
women with breast cancer? 
Until the 1980’s the standard treatment for breast cancer included surgery in 
almost all patients. The concept that endocrine therapy with tamoxifen could 
be an alternative to surgery for older women with breast cancer was proposed 
in the UK in 1982.17 This was based on the fact that 80% of older patients had 
   
oestrogen receptor positive tumours and would be therefore respond to 
treatment with tamoxifen.  This, combined with the high incidence of life 
limiting co-morbidity, formed the rationale for this approach.  A number of 
randomised trials comparing endocrine therapy with tamoxifen versus surgery 
(either with or without adjuvant tamoxifen) were subsequently performed.  
These studies have recently been systematically reviewed and some 
subjected to meta-analysis.26  Seven randomised trials were included in the 
analysis.  All these studies recruited women over the age of 70 with operable 
breast cancer who were fit for surgery under general anaesthesia.  Endocrine 
treatment was with tamoxifen and most of the studies failed to assess 
oestrogen receptor status of the tumours.  Three studies 27 28,29 compared 
surgery without adjuvant tamoxifen to tamoxifen alone.  Four studies 30 4,31,32 
compared surgery with adjuvant tamoxifen to tamoxifen alone.  Surgery 
included mastectomy or wide local excision with or without radiotherapy 
combined with axillary clearance or staging in most of the trials.   
Overall the studies demonstrated that endocrine therapy alone is inferior to 
surgery with adjuvant endocrine therapy for the local control of breast cancer 
in this group of patients.  However, the meta-analysis demonstrated no 
significant difference in overall survival between the two treatments.  One of 
the trials showed a small but significant survival advantage for surgery at 13 
years follow-up.30  Despite the lack of clear evidence of survival benefit for 
surgery, the clear advantage in local disease control has resulted in a 
reduction in the use of primary endocrine therapy in this population of women.   
However recent audits demonstrate the continued use of primary endocrine 
therapy in a substantial proportion of older (over 80 years), less fit patients 
   
with breast cancer in the United Kingdom.2 3,7 These studies demonstrating 
the continued use of primary endocrine therapy in a substantial proportion of 
older women are at variance with the results of a survey of UK breast 
surgeons 98% of whom state that age alone is not relevant in offering surgery 
for the treatment of breast cancer.  However 34% of respondents 
acknowledged that the patient’s biological age is a significant factor although 
less than half utilise any form of assessment of fitness with only a very small 
minority using tools such as comprehensive geriatric assessment.33 These 
findings demonstrate that while surgeons in the UK are open to treating older 
patients with standard approaches including surgery they frequently fail to do 
so predominantly due to concerns about the patient’s fitness and overall life 
expectancy.   
Less information is available on the rates of omission of surgery in other 
countries but recent publications indicate similar trends in other European 
countries.5,6 Despite the publication of a number of studies randomising 
patients to surgery or endocrine therapy and the continued widespread use of 
primary endocrine therapy, little is known about patient attitudes and choices 
in relation to these different options.  Recent small qualitative studies in the 
UK demonstrate that this group of patients generally do not demonstrate 
strong preferences and tend to defer decisions about treatments to their 
physicians with overall high levels of satisfaction with either surgery or primary 
endocrine therapy.34 Clearly there is a need for reliable evidence in this area 
and the ESTEEM trial is a large UK randomised controlled trial addressing 
these issues.  In this study, patients aged 75 and over with primary, operable, 
oestrogen receptor positive breast cancer will be invited to join and are 
   
randomised to receive primary endocrine therapy with an aromatase inhibitor 
(Anastrazole) or surgery and adjuvant Anastrozole.  Importantly this study 
includes assessment of quality of life, patient preferences and cost 
effectiveness in addition to overall survival and control of local disease.   
 
Until evidence from trials such as ESTEEM is available the appropriate 
management of older patients with breast cancer should include adequate 
surgery and appropriate adjuvant therapies in all patients.   In the sub-set of 
patients with a predicted limited life expectancy, due to extreme age or co-
morbidity, the surgical and adjuvant treatments may be modified or in some 
cases omitted.  These approaches are discussed below.  
 
Surgical approaches to the treatment of older patients with breast 
cancer: surgery to the breast 
Primary breast cancer can be managed in the majority of cases by either 
mastectomy or wide local excision.  Numerous studies demonstrate that the 
overall survival of these two approaches is equivalent.  However the most 
recent overview analysis of the Early Breast Cancer Trialists’ Collaborative 
Group demonstrates the importance of adequate local treatment in the 
management of primary operable breast cancer.35 The overview evaluated the 
impact of radiotherapy in patients treated by either breast conserving surgery 
or mastectomy in terms of local control and long-term survival.  There was a 
significant improvement in local control by the addition of radiotherapy to wide 
local excision in patients with lymph node negative and lymph node positive 
disease.  Furthermore there was a significant benefit in local control by the 
   
addition of radiotherapy to the chest wall in patients treated by mastectomy 
where there was axillary node involvement.  The surprising finding of the 
overview was that there was a significant survival advantage at 15 years for 
patients treated with radiotherapy in addition to breast conserving surgery or 
mastectomy.  The benefit in the mastectomy group was predominantly seen in 
patients with axillary node involvement whereas the survival benefit for 
patients treated by breast conservation was independent of nodal status.  
What is the significance of these findings for the management of older 
patients with breast cancer?  The EBCTCG concluded that “in the 
hypothetical absence of other causes of death, about one breast cancer death 
over the next 15 years would be avoided for every four local recurrences 
avoided”.  The implication of this for older women with breast cancer is that 
adequate local control of disease is important and may have a significant 
impact on survival in women with a life expectancy of between 10 to 15 years.  
Therefore for a healthy woman of 70 years of age with a predicted life 
expectancy of 15 years, treatment should follow standard guidelines based on 
evidence from trials recruiting younger women.  However, in women of more 
advanced age or with associated co-morbidity where life expectancy may be 
restricted to less than 5 years it is reasonable to consider alternative 
approaches. 
 
This question of adjuvant radiotherapy after breast conserving surgery in older 
women is addressed in the PRIME trial which aims to establish whether there 
is a cohort of older patients with low risk disease where radiotherapy can be 
omitted. 
   
 The current 'absolute' indications for mastectomy include primary tumours of 
5cm or more in diameter and multi focal disease within more than one 
quadrant of the breast.  Relative indications for mastectomy include smaller 
primary tumour size in patients with small overall breast size, patients with 
central tumours, multi-centric tumours in a single quadrant and patients with 
an extensive in situ component to their invasive cancer.  A further important 
indication for mastectomy is patient choice.  Large audits in the UK continue 
to demonstrate that a significant proportion of patients with small tumours who 
would be eligible for breast conservation surgery will choose mastectomy if 
given a choice.7 
For patients with uni-focal ER positive primary cancers too large to consider 
breast conservation, neoadjuvant treatment with endocrine therapy can be 
utilised to reduce tumour size to permit breast conservation. In this 
neoadjuvant setting, Letrazole has increased efficacy compared to Tamoxifen, 
(55 versus 36% response rate.36 Although there are no data to support the 
use of neo adjuvant chemotherapy in this patient group there are no 
theoretical reasons why this approach should not be considered in patients 
with larger, ER negative tumours.  The role of oncoplastic approaches to 
permit breast conservation are discussed below. 
 
Surgery to the axilla 
The accurate assessment and treatment of axillary metastases from primary 
breast cancer is important for two reasons.  Firstly, where there is clear 
clinical or biopsy proven nodal disease axillary clearance (or adequate 
   
radiotherapy) following a sampling procedure is indicated to prevent local 
progression with the associated potentially distressing symptoms this can 
cause.  The use of preoperative axillary ultrasound and biopsy of suspicious 
nodes is gaining acceptance.  Routine axillary clearance has been 
superseded by less invasive approaches such as sentinel node biopsy or non- 
targeted 4 node sampling.  Sentinel lymph node biopsy (SNB) comprises the 
injection of a radio-labelled colloid and/or blue dye into the breast prior to 
surgery.  At surgery the radioactive and/or blue coloured sentinel nodes are 
identified and removed.  Typically there are one or two such nodes and the 
use of a hand held gamma-probe (with or without pre-operative 
lymphoscintogram) reduces the extent of dissection substantially.  The 
presence of metastases in these nodes is usually confirmed by post-operative 
standard histological assessment but per-operative frozen section, imprint 
cytology or molecular biology approaches can be undertaken with immediate 
completion axillary dissection where axillary nodal metastases are identified.  
A number of studies have demonstrated the accuracy of SNB and the 
improved quality of life associated with this approach when compared to 
axillary node dissection 37-39 SNB is associated with a significant reduction in 
arm related morbidity (lymphoedema) and numbness without any associated 
increase in anxiety in comparison to the axillary node clearance group.  In 
many ways the SNB approach is ideally suited to older patients where the 
potential morbidity associated with more radical axillary surgery may have a 
greater impact on arm function. 
 
   
The second reason for assessing and treating axillary nodal disease is in the 
selection of adjuvant therapies including chemotherapy and radiotherapy.  At 
present the evidence base for the use of chemotherapy in older patients is 
lacking and therefore some authorities argue that staging of the clinically 
(and/or ultrasound) uninvolved axilla is unnecessary.  However other 
therapies may also depend on the extent of axillary nodal disease, particularly 
chest wall radiotherapy following mastectomy.  Therefore in general older 
patients should undergo the same axillary staging and treatment approaches 
as employed in younger women.  At present the utilisation of a completion 
clearance or axillary radiotherapy following a node positive SNB is a matter or 
local treatment preferences but are the subject of randomised clinical trials eg 
the AMAROS study. 
 
Alternative approaches in patients with restricted life expectancy 
There is a small sub-set of patients with a significantly reduced life 
expectancy of 2 to 5 years due to either extreme age or associated co-
morbidity.  As described above the increased use of tools such as 
Comprehensive Geriatric Assessment (CGA) allows these patients to be 
identified and clinicians who routinely treat breast cancer will be immediately 
familiar with such patients who may have extremely limited mobility, impaired 
cognitive function and significant cardiovascular, respiratory and/or renal 
impairment.  Clearly in such patients the surgical treatment of breast cancer is 
unlikely to have any significant impact on life expectancy as these patients are 
more likely to die of causes other than breast cancer.  However, surgical 
treatment may still be appropriate in such patients to avoid the development 
   
of distressing symptoms, such as pain, ulceration and bleeding due to local 
disease progression.  These approaches may include surgery under local or 
regional anaesthesia and the omission or modification of axillary surgery in 
patients where there is no evidence of axillary nodal disease.  For instance a 
lower (level 1) axillary clearance may be preferable to SNB with subsequent 
clearance for node positive patients, where radiotherapy is not an option. In 
general terms, even in frail elderly patients, general anaesthesia is a safe 
option with a mortality of less than 1%.25 Should a full anaesthetic assessment 
indicate that general anaesthesia may be associated with a significant risk 
wide local excision and even mastectomy can be performed under local or 
regional anaesthesia such as intercostal nerve block.40,41 The assessment of 
an anaesthetist experienced in the management of these frail patients is 
essential in the selection of the appropriate anaesthetic technique.   
 
Axillary surgery may be omitted in patients with low life expectancy where 
surgery to the primary tumour may be performed under local anaesthetic.  
This has little impact on overall survival particularly in women aged 75 or over 
and studies indicate a local progression of less than 10%, which, in the 
majority of cases, can be controlled with either further surgery or 
radiotherapy.42,43 
 
As noted previously an alternative to surgery in patients with a reduced life 
expectancy and oestrogen receptor positive disease is primary endocrine 
therapy.  This is particularly relevant in this subset of patients as the majority  
will experience a substantial reduction or complete disappearance of the 
   
primary tumour and associated lymphadenopathy.  The median duration of 
disease control with single agent hormonal therapy is 2-3 years, after which  
disease progression may occur in some patients.  However further response 
to a change in endocrine therapy can be seen as the mechanism of drug 
resistance differs between tamoxifen and the aromatase inhibitors.   
 
Complications of surgery 
The mortality rate for breast cancer surgery is very low even in very old and 
frail women.  Physical complications include scar formation, wound pain, 
seroma formation, haematoma, infection and skin necrosis following 
mastectomy.  The complications of axillary surgery increase with the extent of 
node excision and includes seroma and haematoma, infection, paraesthesia 
and neuropathic pain, mammary oedema, shoulder stiffness and rarely 
damage to the long thoracic nerve resulting in ‘winging’ of scapula.  The most 
significant complication of axillary node clearance is lymphoedema which may 
occur in up to 38% of patients.44 Sentinel node biopsy and axillary sampling 
techniques are associated with a significant reduction in the risk of these 
complications although lymphoedema may occur even following sentinel node 
biopsy.37 The incidence of these complications following surgery is not 
significantly increased by patient age or co-morbidity.45 
 
The psychological impact of the surgical treatment of breast cancer is well 
recognised and the evidence suggests that the psychological morbidity may 
be reduced in the long run by breast conserving techniques although the 
extent of this may be less substantial than initially anticipated. 
   
 The trials comparing primary endocrine therapy with surgery have afforded 
the opportunity to investigate the impact of surgery on psychological well 
being in women with breast cancer.  This demonstrated a short-term negative 
impact of surgery on psychological well being at three months post operatively 
but by 2 years this difference had disappeared.46 
 
Breast reconstruction and onco-plastic surgical techniques 
Over the last 10 years there has been a substantial increase in the rates of 
breast reconstruction following mastectomy.  This has been associated with 
an increase in the range of approaches available for breast conservation such 
as therapeutic mammaplasty and breast re-shaping by volume displacement 
(known as oncoplastic surgical approaches).  These new techniques have 
had a substantial impact in the management of women with breast cancer but 
to date the evidence indicates that older women, particularly those over the 
age of 70 years of age are not benefiting from breast reconstruction or 
oncoplastic approaches despite guidelines which indicate that these 
techniques should be widely available.  There are a number of potential 
reasons for this, including patient and health care professional factors.  Older 
patients may consider the physical impact of the surgical treatment of breast 
cancer less important than younger patients and have fewer concerns about 
body image.47 However, body integrity is an important issue for some patients 
and some case series describe excellent results of breast reconstruction in 
older women.  These report the results of techniques using autologous flaps 
(latissimous dorsi and Transverse Rectus Abdominus Myocutaneous, TRAM 
   
flaps) although in general simple implant based approaches tend to be utilised 
more frequently in older women.48,49 In addition to patient factors the 
extremely low utilisation of breast reconstruction in women over the age of 75 
may indicate that surgeons also have reservations despite the lack of an 
evidence base.  There is no doubt that reconstructive techniques, particularly 
those utilising autologous myocutaneous flaps are more major surgical 
procedures which can be associated with an increased risk of side effects and 
complications such as flap necrosis.  Studies in younger women indicate that 
these complications are more prevalent in patients with associated co-
morbidity and it is this factor which is likely to be influencing surgeons and 
resulting in a failure to offer these options in the older population of women 
with breast cancer.  Patients are also aware of these concerns and this may 
contribute to their decision not to seek breast reconstruction.50  The national 
mastectomy and reconstruction audit being conducted in the United Kingdom 
will provide comprehensive data on this topic within the next few years.  
 
A surgical management strategy for older patients with breast cancer 
In general terms older patients should be considered for standard surgical 
approaches applicable to younger patients wherever possible.  This should 
include the choice of breast conservation or mastectomy where appropriate 
and breast reconstruction or oncoplastic procedures should be included in the 
options available.  The choice of surgical treatment should be decided in 
consultation with the patient after appropriate information has been made 
available.  Following surgery adjuvant therapies including chemotherapy, 
endocrine therapy, radiotherapy and new agents such as Herceptin or 
   
Lapatinib should be considered in accordance with standard protocols.  The 
use of these adjuvant therapies is discussed elsewhere in this special edition.  
The axillary nodal status should be assessed in all suitable patients and nodal 
metastases should be confirmed by preoperative biopsy or sentinel lymph 
node biopsy techniques before proceeding to full axillary node clearance or 
radiotherapy for those patients with nodal disease. 
 
In the subset of patients with impaired life expectancy due to extreme age or 
associated co-morbidity alternative approaches may be considered.  These 
patients should be managed in consultation with specialist geriatricians and 
anaesthetists in addition to surgeons and oncologists.  Appropriate 
assessment tools such as CGA should be utilised and patient preferences 
carefully sought.  An algorithm for the management of these patients is 
outlined in figure 2.   
 
Patients with ER positive tumours may opt for surgery or primary endocrine 
therapy.  In this group of patients surgery may be performed under local or 
regional anaesthesia if patients are not fit for general anaesthesia. 
 
The main aim of surgical treatment in these patients is to avoid the onset of 
distressing symptoms rather than to increase overall survival.  It is therefore 
essential to include patient preferences in the decision making process and to 
undertake procedures which combine the minimum risk with the maximum 
achievable benefit in terms of avoiding morbidity either as a result of the 
surgical procedure or due to disease progression.  In patients with proven 
   
axillary node disease complete clearance should be considered but 
radiotherapy or primary endocrine therapy may be an alternative.  In patients 
with a clinically node negative axilla a sentinel lymph node biopsy under local 
anaesthetic may be employed or axillary surgery omitted, particularly for 
patients on endocrine therapy with oestrogen receptor positive disease. 
 
Summary of recommendations  
This review of the surgical management of older women with breast cancer 
confirms the lack of adequate evidence base for the treatment of this group of 
patients.  However, in the majority of patients with minimal co-morbidity and a 
life-expectancy of greater than 5 years standard surgical approaches can be 
recommended.  For those patients with a reduced life expectancy rational 
modified approaches can be considered.  In all patients careful consideration 
should be given to individual preferences.  In patients with co-morbidity 
comprehensive assessment and the input of a specialist geriatrician and 
anaesthetist should be included in the decision making process.  An 
individualised treatment plan should be developed in the context of an 
extended multi-disciplinary team.  Ideally these patients will be managed in a 
specialist clinic setting with all the appropriate clinical specialists available to 
form an integrated assessment and treatment plan.21 
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Fig.2 
Management of breast cancer in patients with limited life expectancy or not fit for 
surgery under general anaesthetic 
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Fig. 1: Eurocare3/National Office of Statistics. Cases diagnosed from 1990-1994 followed up to 1999 
Comparison of the 5 year relative survival fo female breast 
cancer patients in Europe and the USA
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